Cell Genesys Company Update  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Mar 31 Calls Today's Calls

Call Details Cell Genesys Company Update Mon, Mar 31, 2008, 4:30 pm Eastern Listen to the archived event audio About Cell Genesys (NasdaqGM:CEGE) Other Calls  Cell Genesys, Inc., a biotechnology company, engages in the development and commercialization of biological therapies for patients with cancer. It develops cell-based cancer immunotherapies and oncolytic virus therapies. The company’s GVAX cancer Immunotherapies comprise Prostate Cancer, a phase III product for the treatment of prostate cancer; Pancreatic Cancer, a phase II product for pancreatic cancer; and Leukemia, a phase II product for the treatment of acute and chronic myelogenous leukemia, and myelodysplastic syndrome. Its Oncolytic Virus Therapy includes CG0070, a phase I product for the treatment of recurrent bladder cancer. Cell Genesys has alliance with Novartis AG for the development and commercialization of oncolytic virus therapies; research and development collaboration with Medarex, Inc.; and development and commercialization collaboration of GVAX immunotherapy with Takeda Pharmaceutical Company Limited for prostate cancer. The company was founded in 1988 and is headquartered in South San Francisco, California. More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Insider | Financials | Analyst Ratings